Select a year:
Select a category:

4P-Pharma at BIO Digital 2021

4P-Pharma will attend the upcoming BIO International Convention held virtually as BIO Digital, on June 10-11 & 14-18, 2021, as part of the Business France virtual French pavilion. Contact Roselina Lam, our Business Development and Licensing Manager, via the partnering platform or by e-mail, to learn more about us and discuss future partnerships. She is looking forward&hellip

Read More

The OA-BIO European Consortium, led by 4Moving Biotech, awarded a Eurostars grant to develop 4P004 through a biomarkers-driven approach

4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers.&hellip

Read More

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people&hellip

Read More

4Moving Biotech at the OARSI Connect 2021 online event

A poster on our latest results on 4P004 entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (#435) will be presented during the OARSI Connect online event on 2021 April 29-May 1, by Pr. Francis Berenbaum (4Moving Biotech’s CEO/CMO, Head of Rheumatology department at Saint-Antoine Hospital, and Professor of Rheumatology at Sorbonne University, in Paris, France).&hellip

Read More

4P-Pharma at BIO Europe Spring 2021

Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 22nd-25th, 2021, delivered digitally. Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships. She is looking forward to meet you there!

Read More

4Moving Biotech received the Seal of Excellence from the European Commission

4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis. The Seal of Excellence is a high-quality label awarded by a panel&hellip

Read More